Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain (Q40939119)

25 September 2017

title

Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain (English)

1 reference

25 September 2017

Sol-Bi Shin

1

1 reference

25 September 2017

Sang-Uk Woo

series ordinal

2

1 reference

25 September 2017

Hyungshin Yim

series ordinal

3

1 reference

25 September 2017

publication date

14 May 2015

1 reference

Journal of Cellular Physiology

25 September 2017

published in

1 reference

25 September 2017

volume

230

1 reference

25 September 2017

issue

12

1 reference

25 September 2017

page(s)

3057-3067

1 reference

Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition

25 September 2017

cites work

1 reference

Polo-like kinases and the orchestration of cell division

21 January 2018

1 reference

Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells

21 January 2018

1 reference

Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis

21 January 2018

1 reference

Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates

21 January 2018

1 reference

The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain

21 January 2018

1 reference

Bub1 and BubR1: at the interface between chromosome attachment and the spindle checkpoint

21 January 2018

1 reference

Discovery of thiophene inhibitors of polo-like kinase

21 January 2018

1 reference

Thymoquinone: a promising anti-cancer drug from natural sources

21 January 2018

1 reference

Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes.

21 January 2018

1 reference

Polo-like kinases inhibitors.

21 January 2018

1 reference

Catalytic assembly of the mitotic checkpoint inhibitor BubR1-Cdc20 by a Mad2-induced functional switch in Cdc20.

21 January 2018

1 reference

Polo boxes come out of the crypt: a new view of PLK function and evolution.

21 January 2018

1 reference

Functional studies on the role of the C-terminal domain of mammalian polo-like kinase

21 January 2018

1 reference

Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom

21 January 2018

1 reference

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

21 January 2018

1 reference

Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint

21 January 2018

1 reference

p150(Sal2) is a p53-independent regulator of p21(WAF1/CIP)

21 January 2018

1 reference

Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression.

21 January 2018

1 reference

Normal cells, but not cancer cells, survive severe Plk1 depletion

21 January 2018

1 reference

Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase.

21 January 2018

1 reference

Progress in the discovery of polo-like kinase inhibitors.

21 January 2018

1 reference

Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions

21 January 2018

1 reference

Centrosomal protein FOR20 is essential for S-phase progression by recruiting Plk1 to centrosomes.

21 January 2018

1 reference

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

21 January 2018

1 reference

Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition

21 January 2018

1 reference

Current clinical trials with polo-like kinase 1 inhibitors in solid tumors

21 January 2018

1 reference

Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation

21 January 2018

1 reference

Plk1-targeted therapies in TP53- or RAS-mutated cancer

21 January 2018

1 reference

Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1

21 January 2018

1 reference

DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCP.25042

1 reference

25 September 2017

1 reference